Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
MSD Curbs Supply of HPV Vaccines in Japan amid Catch-Up Demand
MSD has started restricting shipments of its HPV vaccines in Japan as the number of people receiving such shots has spiked ahead of the expiration of the government’s “catch-up” program in March next year. Subject to the measure, announced on…
To read the full story
Related Article
- Panel OKs 1-Year Extension of HPV Catch-Up Vaccinations, with Strings Attached
November 28, 2024
- Japan Likely to Extend “Catch-Up” HPV Vaccination Program
November 26, 2024
- MHLW Asks for Ramp Up of HPV Vaccines after 5-Fold Rise in Demand
October 11, 2024
BUSINESS
- Will Unlisted AGs Rush for June Listing or Be Left on Ice?
January 23, 2026
- Enhertu Reels in 6th China Indication in Second-Line Gastric Cancer
January 23, 2026
- Maruho Out-Licenses Rapifort to Taiwan’s Orient EuroPharma
January 23, 2026
- Towa to Take Over Manufacturing of Otsuka’s LLPs in Cross-Sector Tie-Up
January 22, 2026
- Otsuka/Ionis’ HAE Drug Dawnzera Approved in Europe
January 22, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…